XCNQMVMD
Market cap6mUSD
Dec 23, Last price
0.03CAD
1D
25.00%
1Q
-28.57%
IPO
-80.77%
Name
Mountain Valley MD Holdings Inc
Chart & Performance
P/E
—
P/S
146.81
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
94.92%
Rev. gr., 5y
%
Revenues
60k
Net income
-8m
L+3.06%
CFO
-3m
L-31.19%
Profile
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 60 | 110 | |||||||
Cost of revenue | 3,246 | 5,551 | 9,401 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,186) | (5,551) | (9,291) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (92) | 109 | 336 | ||||||
Tax Rate | |||||||||
NOPAT | (3,094) | (5,660) | (9,627) | ||||||
Net income | (7,670) 3.06% | (7,442) -23.35% | (9,709) 19.23% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (3,204) | 395 | |||||||
BB yield | 16.20% | -0.80% | |||||||
| Debt | |||||||||
Debt current | 6 | 38 | |||||||
Long-term debt | 6 | 50 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (6,844) | (11,247) | (19,587) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (3,296) | (4,790) | (5,587) | ||||||
CAPEX | (496) | (64) | (98) | ||||||
Cash from investing activities | (503) | 1,885 | (98) | ||||||
Cash from financing activities | (1,602) | 395 | |||||||
FCF | (3,291) | (6,518) | (10,037) | ||||||
| Balance | |||||||||
Cash | 5,915 | 9,714 | 14,221 | ||||||
Long term investments | 929 | 1,545 | 5,454 | ||||||
Excess cash | 6,841 | 11,259 | 19,670 | ||||||
Stockholders' equity | 414 | 24,262 | 41,947 | ||||||
Invested Capital | 8,294 | 4,816 | 5,222 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 329,653 | 329,653 | 329,237 | ||||||
Price | 0.06 0.00% | 0.06 -60.00% | 0.15 -87.39% | ||||||
Market cap | 19,779 0.00% | 19,779 -59.95% | 49,386 -84.25% | ||||||
EV | 12,935 | 21,558 | 51,495 | ||||||
EBITDA | (2,770) | (5,106) | (8,840) | ||||||
EV/EBITDA | |||||||||
Interest | 3,832 | 5 | |||||||
Interest/NOPBT | |||||||||